Drug Trial Radar · NCT04253132
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
Last checked: Nov 19, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
24
Planned (sponsor's estimate)
Start
Jan 1, 2021
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- NeuroTau, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Cleveland Clinic
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12-week study of oral tolfenamic acid vs. placebo in Progressive Supranuclear Palsy (PSP)
Conditions
- Progressive Supranuclear Palsy
Interventions
Tolfenamic AcidDrug
Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
PlacebosDrug
oral placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerance of tolfenamic acid in individuals with PSPTime frame: 12-weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lou Ruvo Center for Brain Health - Cleveland Clinic Nevada
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.